Ákos Kalina

Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 −2518 G/G genotype in CAD patients

Csaba Szalai, J. Duba, Zoltán Prohászka et al. · Atherosclerosis · 2001 · 315 citations · Full text

Vascular Disease, Cardiovascular Epidemiology, Cardiovascular Disease +14

Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction

Burkert Pieske, Rolf Wachter, Sanjiv J. Shah et al. · JAMA · 2021 · 155 citations · Full text

Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy

Henry N. Ginsberg, Neil Hounslow, Yusuke Senko et al. · Diabetes Care · 2022 · 50 citations · Full text

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial

Eliot A. Brinton, Uma Kher, Sukrut Shah et al. · Journal of clinical lipidology · 2014 · 27 citations

Specific Patient Subgroups, Pharmacology, Cetp Inhibition +6

The association of serum lipoprotein(a) levels, apolipoprotein(a) size and (TTTTA) polymorphism with coronary heart disease

Ákos Kalina, Albert Császár, George Füst et al. · Clinica Chimica Acta · 2001 · 24 citations

Cardiovascular Epidemiology, Cardiovascular Disease, Genetic Epidemiology +11